pioglitazone has been researched along with Rupture, Spontaneous in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Rupture, Spontaneous: Tear or break of an organ, vessel or other soft part of the body, occurring in the absence of external force.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakashiro, S | 1 |
| Matoba, T | 1 |
| Umezu, R | 1 |
| Koga, J | 1 |
| Tokutome, M | 1 |
| Katsuki, S | 1 |
| Nakano, K | 1 |
| Sunagawa, K | 1 |
| Egashira, K | 1 |
1 other study available for pioglitazone and Rupture, Spontaneous
| Article | Year |
|---|---|
Pioglitazone-Incorporated Nanoparticles Prevent Plaque Destabilization and Rupture by Regulating Monocyte/Macrophage Differentiation in ApoE-/- Mice.
Topics: Administration, Intravenous; Angiotensin II; Animals; Apolipoproteins E; Atherosclerosis; Brachiocep | 2016 |